The FDA has approved Eli Lilly's oral GLP-1 weight-loss medication, Foundayo, for adults with obesity or overweight, marking a significant new option in obesity treatment, according to Healthline News. The once-daily pill can be taken with or without food and is designed to be used alongside diet and exercise as part of weight management.
Eli Lilly's approval of Foundayo positions the drug as a direct competitor to Novo Nordisk’s widely used GLP-1 injection, Wegovy, with the potential to capture a substantial share of the growing market, estimated to generate up to $2 billion in US sales by 2026, TheStreet reports. This approval comes ahead of schedule, reflecting strong demand for GLP-1 based weight loss therapies.
To increase patient access, Amazon Pharmacy has launched same-day delivery of Foundayo in thousands of cities nationwide, leveraging its logistics network to enable faster and more convenient access to the medication, Inc Magazine and Quartz detail. Amazon’s service also includes availability through One Medical kiosks, with insurance pricing starting as low as $1 per day.
Amazon’s expansion into the weight management space through this offering underscores a strategic move to deepen its role in healthcare delivery and patient engagement, TheStreet reports. This integration aims to provide a seamless experience from prescription to home delivery, thereby enhancing adherence and treatment outcomes.
Looking ahead, the entry of Foundayo into the market alongside established injectable GLP-1 drugs will be closely watched for its impact on treatment patterns, pricing dynamics, and patient choice in obesity care. Stakeholders will assess how the oral format influences long-term usage and whether rapid delivery services like Amazon Pharmacy become a standard in pharmaceutical distribution.
Amazon Pharmacy
David Ricks
Foundayo
Eli Lilly
FDA
Amazon
